SCHEMBL7556598

SCHEMBL7556598

O=C(C(Cc1ccccc1)N1CCNCC1)N1CCc2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.69
HTT P42858 1/20 0.65
RECQL P46063 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
ALDH1A1 P00352 4/20 0.55
FPR2 P25090 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NFKB1 P19838 3/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
TP53 P04637 2/20 0.48
MAPK1 P28482 2/20 0.48
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7556587 0.80 TSHR (0.54) TSHRHTTRECQLNPSR1ALDH1A1
SCHEMBL4463271 0.78 LMNA (0.68) RECQLNPSR1ALDH1A1RAB9AL3MBTL1
SCHEMBL2374151 0.77 TSHR (0.67) TSHRHTTRECQLNPSR1ALDH1A1
SCHEMBL2374156 0.77 TSHR (0.67) TSHRHTTRECQLNPSR1ALDH1A1
SCHEMBL11251072 0.75 SLC6A4 (0.55) NPSR1ALDH1A1RAB9AL3MBTL1LMNA
SCHEMBL6421876 0.75 LMNA (0.64) RECQLNPSR1ALDH1A1RAB9AL3MBTL1
SCHEMBL7556586 0.74 ALDH1A1 (0.52) TSHRHTTRECQLNPSR1ALDH1A1
SCHEMBL9309772 0.74 SLC6A4 (0.50) RECQLL3MBTL1MAPTLMNAKDM4E
SCHEMBL14156333 0.72 ALDH1A1 (1.00) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL4039568 0.72 SLC6A4 (0.51) RECQLNPSR1RAB9AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones NEUROGEN CORPORATION. 2002-09-12 US disclosed
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones NEUROGEN CORPORATION. 2002-09-12 US disclosed
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones NEUROGEN CORPORATION. 2002-09-12 US disclosed
US-6355644-B1 NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER NEUROGEN CORPORATION 2002-03-12 US disclosed
US-6355644-B1 NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER NEUROGEN CORPORATION 2002-03-12 US disclosed
US-6355644-B1 NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER NEUROGEN CORPORATION 2002-03-12 US disclosed
WO-2000076967-A1 BENZYLPIPERAZINYL-INDOLINYLETHANONES NEUROGEN CORPORATION (US) 2000-12-21 WO disclosed
WO-2000076967-A1 BENZYLPIPERAZINYL-INDOLINYLETHANONES NEUROGEN CORPORATION (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones GABRP, GABBR1, GABARAP TSHR 1775/4885HTT 237/4885RECQL 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.